Sign In
Buy XBIT
$2.23
-0.0100 (-0.446%)
At Close: Jul 31, 2026
FDA Gives Go-Ahead for XBiotech's Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer
04:00am, Monday, 19'th Apr 2021
XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer
Top Small-Cap Stocks for March 2021
06:45pm, Friday, 26'th Feb 2021
These are the small-cap stocks with the best value, fastest growth, and most momentum for March 2021.
XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain
08:15am, Thursday, 21'st Jan 2021
With New Infectious Strain Rapidly Spreading, XBiotech Establishes Data Indicating its Candidate True Human™ COVID-19 Therapy may be Effective for Treating New Mutant Strain With New Infectious Stra
XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy
08:15am, Tuesday, 19'th Jan 2021
Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D. Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg A
XBiotech: New Q1 2021 Clinical Announcement, 9M 2020 Confirmed Short-Term Janssen Revenues, 2022 Is Uncertain, +28% Upside
05:05pm, Thursday, 19'th Nov 2020
XBiotech Inc. is a clinical-stage biopharmaceutical company focused on developing safer/more effective therapeutics through human-based monoclonal antibodies. XBiotech's pipeline consists of 4 candida
XBiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-COVID-19 Therapeutic Cocktail
08:15am, Thursday, 19'th Nov 2020
Candidate Therapy for Flu+Covid-19 Co-infection Shows Potent Anti-Viral Potential Candidate Therapy for Flu+Covid-19 Co-infection Shows Potent Anti-Viral Potential
5 Ben Graham Lost Formula Stocks With High Financial Strength
04:26pm, Wednesday, 28'th Oct 2020
As markets continue sliding on economic recovery slowdown fears, five Ben Graham Lost Formula stocks with high financial strength are Sabine Royalty Trust (NYSE:SBR), XBiotech Inc. (NASDAQ:XBIT), Cata
